Oxford University Press

SHERPA: Yellow

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Mellinghoff
    Mellinghoff
  4. Shuman
    Shuman
  5. Rosenblum
    Rosenblum
  6. Dunkel
    Dunkel
  7. Karajannis
    Karajannis
  8. Saltz
    Saltz
  9. Souweidane
    Souweidane
  10. Panageas
    Panageas

Groups

  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)
  7. Department of Pathology and Laboratory Medicine (415)
  8. Gastrointestinal Oncology Service (386)
  9. Genitourinary Oncology Service (367)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2107)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (92)
  5. Editorial (84)
  6. Guidelines (36)
  7. Correspondence (26)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (10)
Groups
  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Stewart Shuman (88)
  6. Marc Rosenblum (87)

More People

Years
  1. 2025 (105)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1670)
  2. Neuro-Oncology (846)
  3. JNCI: Journal of the National Cancer Institute (485)
  4. Nucleic Acids Research (210)
  5. Clinical Infectious Diseases (138)
  6. American Journal of Clinical Pathology (106)

More Publications

Results (4652)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Treatment (Tx) sequencing with tepotinib in previously treated patients (pts) with MET exon 14 (METex14) skipping NSCLC in the VISION trial
    Meeting Abstract

    Viteri, S.; Felip, E.; Griesinger, F.; Garassino, M. C.; Sakai, H.; Le, X.; Veillon, R.; Smit, E. F.; Raskin, J.; Thomas, M.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK plus ) advanced solid tumors, including NSCLC: Update from the phase I/II TRIDENT-1 trial
    Meeting Abstract

    Solomon, B. J.; Drilon, A.; Lin, J. J.; Bazhenova, L.; Goto, K.; De Langen, J.; Kim, D. W.; Wolf, J.; Springfeld, C.; Popat, S.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Intracranial efficacy of HER3-DXd in patients with previously treated advanced EGFR-mutated NSCLC: Results from HERTHENA-Lung01
    Meeting Abstract

    Johnson, M. L.; Jänne, P. A.; Goto, Y.; Yoh, K.; Lee, S. H.; Paz-Ares, L.; Besse, B.; Novello, S.; Hayashi, H.; Kim, D. W.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Quality of life (QoL) outcomes in patients (pts) with zanidatamab (zani)-treated HER2-positive (HER2+) biliary tract cancer (BTC) in the phase IIb HERIZON-BTC-01 study
    Meeting Abstract

    Wasan, H. S.; Harding, J. J.; Fan, J.; Oh, D. Y.; Choi, H. J.; Kim, J. W.; Chang, H. M.; Bao, L.; Sun, H.; Macarulla, T.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Phase II study of cabozantinib in patients with MET-altered lung cancers
    Meeting Abstract

    Harada, G.; Santini, F. C.; Repetti, R. W.; Chang, J.; Yang, S. R.; Lin, Y. T.; Moses, K. A.; Falcon, C.; Wilhelm, C. J.; Goldstein, M.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Analysis of data from the AENEAS study assessing the third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), aumolertinib, and virtual comparison with osimertinib
    Meeting Abstract

    LaRose, M.; Zhou, M.; Lu, S.; Wei, H.; Bates, S. E.; Schwartz, L.; Fojo, A. T.
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Liquid biopsies (LBx) and tissue biopsies (TBx) for identifying MET exon 14 (METex14) skipping in advanced NSCLC: Analyses from the phase II VISION study of tepotinib
    Meeting Abstract

    Rolfo, C. D.; Grupp, A. M. O.; Menzel, C.; Bruns, R.; Juraeva, D.; Stroh, C.; Johne, A.; Paik, P. K.
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Schram, A.; Goto, K.; Kim, D. W.; Hollebecque, A.; Rha, S. Y.; Nishino, K.; Duruisseaux, M.; Umemoto, K.; Park, J. O.; Leighl, N.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2 (ERBB2)-mutant (HER2m) metastatic nonesmall cell lung cancer (NSCLC) with and without brain metastases (BMs): Pooled analyses from DESTINY-Lung01 and DESTINY-Lung02
    Meeting Abstract

    Li, B. T.; Planchard, D.; Goto, K.; Smit, E. F.; De Langen, J.; Goto, Y.; Ninomiya, K.; Kubo, T.; Pérol, M.; Felip, E.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Genomics of early progression on selpercatinib in patients with RET fusion-positive lung cancers
    Meeting Abstract

    Chen, M. F.; Rosen, E.; Falcon, C.; Repetto, M.; Yang, S. R.; Chang, J.; Kris, M. G.; Rekhtman, N.; Donoghue, M.; Drilon, A.
    Annals of Oncology (2023)

    Fulltext@MSK | Save